Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19
Interleukin-6 (IL-6) has been linked to several life-threatening disease processes. Developing a point-of-care testing platform for the immediate and accurate detection of IL-6 concentrations could present a valuable tool for improving clinical management in patients with IL-6-mediated diseases. Dra...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/5/1164 |
| _version_ | 1797500452276797440 |
|---|---|
| author | Johnny Atallah Dakota Archambault Jeffrey D. Randall Adam Shepro Lauren E. Styskal David R. Glenn Colin B. Connolly Katelin Katsis Kathleen Gallagher Musie Ghebremichael Michael K. Mansour |
| author_facet | Johnny Atallah Dakota Archambault Jeffrey D. Randall Adam Shepro Lauren E. Styskal David R. Glenn Colin B. Connolly Katelin Katsis Kathleen Gallagher Musie Ghebremichael Michael K. Mansour |
| author_sort | Johnny Atallah |
| collection | DOAJ |
| description | Interleukin-6 (IL-6) has been linked to several life-threatening disease processes. Developing a point-of-care testing platform for the immediate and accurate detection of IL-6 concentrations could present a valuable tool for improving clinical management in patients with IL-6-mediated diseases. Drawing on an available biobank of samples from 35 patients hospitalized with COVID-19, a novel quantum-magnetic sensing platform is used to determine plasma IL-6 concentrations. A strong correlation was observed between IL-6 levels measured by QDTI10x and the Luminex assay (r = 0.70, <i>p</i>-value < 0.001) and between QDTI80x and Luminex (r = 0.82, <i>p</i>-value < 0.001). To validate the non-inferiority of QDTI to Luminex in terms of the accuracy of IL-6 measurement, two clinical parameters—the need for intensive care unit admission and the need for mechanical intubation—were chosen. IL-6 concentrations measured by the two assays were compared with respect to these clinical outcomes. Results demonstrated a comparative predictive performance between the two assays with a significant correlation coefficient. Conclusion: In short, the QDTI assay holds promise for implementation as a potential tool for rapid clinical decision in patients with IL-6-mediated diseases. It could also reduce healthcare costs and enable the development of future various biomolecule point-of-care tests for different clinical scenarios. |
| first_indexed | 2024-03-10T03:03:05Z |
| format | Article |
| id | doaj.art-a27d5826d4cf42e7a26498a53c3a33ba |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T03:03:05Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-a27d5826d4cf42e7a26498a53c3a33ba2023-11-23T10:40:16ZengMDPI AGDiagnostics2075-44182022-05-01125116410.3390/diagnostics12051164Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19Johnny Atallah0Dakota Archambault1Jeffrey D. Randall2Adam Shepro3Lauren E. Styskal4David R. Glenn5Colin B. Connolly6Katelin Katsis7Kathleen Gallagher8Musie Ghebremichael9Michael K. Mansour10Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USADivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USAQuantum Diamond Technologies Inc., Somerville, MA 02143, USAQuantum Diamond Technologies Inc., Somerville, MA 02143, USAQuantum Diamond Technologies Inc., Somerville, MA 02143, USAQuantum Diamond Technologies Inc., Somerville, MA 02143, USAQuantum Diamond Technologies Inc., Somerville, MA 02143, USADepartment of Medicine, Harvard Medical School, Boston, MA 02115, USADepartment of Medicine, Harvard Medical School, Boston, MA 02115, USADepartment of Medicine, Harvard Medical School, Boston, MA 02115, USADivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USAInterleukin-6 (IL-6) has been linked to several life-threatening disease processes. Developing a point-of-care testing platform for the immediate and accurate detection of IL-6 concentrations could present a valuable tool for improving clinical management in patients with IL-6-mediated diseases. Drawing on an available biobank of samples from 35 patients hospitalized with COVID-19, a novel quantum-magnetic sensing platform is used to determine plasma IL-6 concentrations. A strong correlation was observed between IL-6 levels measured by QDTI10x and the Luminex assay (r = 0.70, <i>p</i>-value < 0.001) and between QDTI80x and Luminex (r = 0.82, <i>p</i>-value < 0.001). To validate the non-inferiority of QDTI to Luminex in terms of the accuracy of IL-6 measurement, two clinical parameters—the need for intensive care unit admission and the need for mechanical intubation—were chosen. IL-6 concentrations measured by the two assays were compared with respect to these clinical outcomes. Results demonstrated a comparative predictive performance between the two assays with a significant correlation coefficient. Conclusion: In short, the QDTI assay holds promise for implementation as a potential tool for rapid clinical decision in patients with IL-6-mediated diseases. It could also reduce healthcare costs and enable the development of future various biomolecule point-of-care tests for different clinical scenarios.https://www.mdpi.com/2075-4418/12/5/1164IL-6COVID-19diagnosticsICUmechanical ventilationLuminex |
| spellingShingle | Johnny Atallah Dakota Archambault Jeffrey D. Randall Adam Shepro Lauren E. Styskal David R. Glenn Colin B. Connolly Katelin Katsis Kathleen Gallagher Musie Ghebremichael Michael K. Mansour Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19 Diagnostics IL-6 COVID-19 diagnostics ICU mechanical ventilation Luminex |
| title | Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19 |
| title_full | Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19 |
| title_fullStr | Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19 |
| title_full_unstemmed | Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19 |
| title_short | Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19 |
| title_sort | rapid quantum magnetic il 6 point of care assay in patients hospitalized with covid 19 |
| topic | IL-6 COVID-19 diagnostics ICU mechanical ventilation Luminex |
| url | https://www.mdpi.com/2075-4418/12/5/1164 |
| work_keys_str_mv | AT johnnyatallah rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT dakotaarchambault rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT jeffreydrandall rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT adamshepro rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT laurenestyskal rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT davidrglenn rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT colinbconnolly rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT katelinkatsis rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT kathleengallagher rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT musieghebremichael rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 AT michaelkmansour rapidquantummagneticil6pointofcareassayinpatientshospitalizedwithcovid19 |